去氨加压素对伤前服用抗血小板药物的轻度创伤性脑损伤患者血肿扩大的作用
本研究回顾性纳入2012年7月至2018年5月单中心I级创伤中心收治的202例伤前服用抗血小板药物的成人TBI患者,其中158例(78%)接受去氨加压素(DDAVP)治疗。血肿扩大发生率在DDAVP组为14%、未用DDAVP组为30%(p=0.015),多因素校正后DDAVP与血肿扩大的关联仍显著(校正OR 0.259,95%CI 0.103-0.646,p=0.004)。血栓事件两组相似(DDAVP组2.5% vs 未用组4.5%,p=0.613)。作者结论认为DDAVP与较低血肿扩大发生率相关,并认为这些结果支持开展随机对照试验进一步评估该适应证。
要点
- 伤前服用抗血小板药物的轻度TBI患者中,接受DDAVP者血肿扩大发生率14%,未接受者30%(p=0.015)。
- 校正年龄、损伤严重度评分、多腔出血及伤前高剂量阿司匹林(>81 mg)、ADP受体抑制剂、口服抗凝药、凝血酶原复合物或血小板等因素后,DDAVP与血肿扩大的关联仍显著(校正OR 0.259,95%CI 0.103-0.646,p=0.004)。
- 血栓事件两组相似:DDAVP组2.5% vs 未用DDAVP组4.5%(p=0.613)。
- 研究为回顾性设计,作者结论认为结果支持开展随机对照试验进一步评估DDAVP在该适应证中的作用。
适用人群与场景
- 2012年7月至2018年5月连续入住I级创伤中心的成人患者,伤前处方抗血小板药物,且CT扫描显示脑出血。
- 排除:住院时间<24小时者、DDAVP经非静脉途径给药者、DDAVP剂量<0.3 mcg/kg者、CT扫描无脑出血证据者。
- 人群中位特征:平均年龄76±12岁;最常见损伤机制为跌倒(76%);69%为急性硬膜下血肿,49%为多腔出血;91%患者初始GCS 13-15分。
处置流程与药物剂量
- DDAVP经静脉给药,剂量≥0.3 mcg/kg(原文排除剂量<0.3 mcg/kg者,未报告具体给药频次和疗程)。
研究设计与关键结果
- 回顾性研究,纳入202例患者,其中158例(78%)接受DDAVP;最常见抗血小板方案为阿司匹林(N=151,75%),其次为双联抗血小板方案(N=26,13%)和ADP受体抑制剂(N=25,12%)。
- 血肿扩大发生率:DDAVP组14% vs 未用DDAVP组30%(p=0.015)。
- 多因素分析校正年龄、损伤严重度评分、多腔出血及伤前高剂量阿司匹林(>81 mg)、ADP受体抑制剂、口服抗凝药、凝血酶原复合物或血小板后,DDAVP与血肿扩大的关联仍显著(校正OR 0.259,95%CI 0.103-0.646,p=0.004)。
- 血栓事件:DDAVP组2.5% vs 未用DDAVP组4.5%(p=0.613)。
证据类型、等级与局限
- 研究类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,DDAVP与伤前服用抗血小板药物的轻度TBI患者较低的血肿扩大发生率相关,这些结果支持开展随机对照试验进一步评估DDAVP在该适应证中的作用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND/OBJECTIVE: Desmopressin (DDAVP) has been suggested for antiplatelet medication reversal in patients with traumatic brain injury (TBI) but there are limited data describing its effect on clinical outcomes. The purpose of this study was to evaluate the effect of DDAVP on hematoma expansion and thrombosis in patients with TBI who were prescribed pre-injury antiplatelet medications.
METHODS: Consecutive adult patients who were admitted to our level I trauma center and prescribed pre-injury antiplatelet medications between July, 2012, and May, 2018, were retrospectively identified. Patients were excluded if their hospital length of stay was < 24 h, if DDAVP was administered by any route other than intravenous, if they received a DDAVP dose < 0.3 mcg/kg or there was no evidence of brain hemorrhage on computed tomography (CT) scan. Patients were stratified based on the use of DDAVP, and the incidence of hematoma expansion was compared between groups. Thrombotic events were reviewed as a secondary outcome. Multivariate analysis was utilized to control for confounding variables.
RESULTS: Of 202 patients included in analysis, 158 (78%) received DDAVP. The mean age was 76 ± 12 years; the most common injury mechanism was falls (76%); 69% had acute subdural hematoma, and 49% had multi-compartmental hemorrhage. Initial Glasgow coma score was between 13 and 15 for 91% of patients. Aspirin was the most common antiplatelet regimen prescribed (N = 151, 75%), followed by dual antiplatelet regimens (N = 26, 13%) and adenosine diphosphate (ADP)-receptor inhibitors (N = 25, 12%). The incidence of hematoma expansion was 14% and 30% for patients who did and did not receive DDAVP, respectively (p = 0.015). After controlling for age, injury severity score, multi-compartmental hemorrhage, and receipt of pre-injury high-dose aspirin (> 81 mg), ADP-receptor inhibitors, oral anticoagulants, prothrombin complex concentrates or platelets in a multivariate analysis, the association between DDAVP and hematoma expansion remained significant (adjusted OR 0.259 [95% CI 0.103-0.646], p = 0.004). Thrombotic events were similar between the two groups (DDAVP, 2.5%, no DDAVP, 4.5%; p = 0.613).
CONCLUSIONS: DDAVP was associated with a lower incidence of hematoma expansion in patients with mild TBI who were prescribed pre-injury antiplatelet medications. These results justify a randomized controlled trial to further evaluate the role of DDAVP for this indication.
参考来源
- Barletta JF, Abdul-Rahman D, Hall ST, et al. The Role of Desmopressin on Hematoma Expansion in Patients with Mild Traumatic Brain Injury Prescribed Pre-injury Antiplatelet Medications. Neurocrit Care. 2020. PMID: 31898177. doi:10.1007/s12028-019-00899-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。